Successful treatment of early intervention with tacrolimus for a patient with lupus nephritis III + V

Japanese Journal of Clinical Immunology

Volumn 31, Issue 6, 2008, Pages 460-464

  Yoshida, Shuzo ^a   Kotani, Takuya ^a   Takeuchi, Tohru ^a   Isoda, Kentaro ^a   Hata, Kenichiro ^a   Watanabe, Koko ^a   Shoda, Takeshi ^a   Inoue, Toru ^a   Makino, Shigeki ^a   Hanafusa, Toshiaki ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Lupus nephritis; membranous nephritis; Tacrolimus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ARTICLE; CASE REPORT; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MIDDLE AGED;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MIDDLE AGED; TACROLIMUS;

EID: 76649135697     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.31.460     Document Type: Article

References (15)

1. Trager J., et al.: Mortality and causes of death in systemic lupus erythematosus. Curr Opin in Rheumatol. 13: 345–351, 2001.
2. Weening J. J., et al.: The classification of glomerulonephritis in systemic lupus erythematosus. Kidney Int. 65: 521–530, 2004.
3. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL).: Lupus nephrtis:Prognostic factors and probability of maintaining life supporting renal function 10 years after diagnosis. Am J Kidney Dis. 19: 473–479, 1992.
4. Donadio J. V., Jr., et al.: Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus. 4: 109–115, 1995.
5. Huong D. L., et al.: Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine (Baltimore). 78: 148–166, 1999.
6. Mercadal L., et al.: Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant. 17: 1771–1778, 2002.
7. Maruyama M., et al.: Good response of membranous lupus nephritis to tacrolimus. Clinical Nephrology. 65: 276–279, 2006.
8. Tse K. C., et al.: A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus. 16: 46–51, 2007.
9. Tanaka H., et al.: Effective treatment of young patients with prediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study. Lupus. 16: 896–900, 2007.
10. Moc C. C., et al.: Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis. 43: 269–276, 2004.
11. Chan T. M., et al.: Treatment of membranous lupus nephritis with nephritic syndrome by sequential immunosuppression. Lupus. 8: 545–551, 1999.
12. Radhakrishnan J., et al.: Cyclosporine treatment of lupus membtanous nephropathy. Clin Nephrol. 42: 147–154, 1994.
13. Hallegua D., et al.: Cyclosporine for lupus membranous nephritis:experience with ten patients and lupus membranous nephritis: experience with ten patients and review of the literature. Lupus. 9: 241–251, 2000.
14. Austin H. A., et al.: Membranous lupus nephritis. Lupus. 14: 65–71, 2005.
15. Boumpas D. T., et al.: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 340: 741–745, 1992.